Pioneering the Localization of
Plasma Fractionation Processes
A significant portion of the country's therapeutic need for plasma-derived products requires achieving technological independence in the fractionation chain.
nojine Biopharma, as one of the modern pillars of pharmaceutical biotechnology in the country, was established with the goal of achieving national self-sufficiency in the production of albujine and immunoglobulins. By replacing traditional methods and integrating modern membrane filtration knowledge, we strive to take a strategic step toward ensuring the country's pharmaceutical supply security and improving the quality of life for patients with special conditions.
.webp)
Self-Sufficiency Geography & Value Chain
Research & Production Infrastructure
The physical and scientific chain of nojine Biopharma guarantees research and mass production of biological products through two parallel and coordinated arms. By bridging the academic environment and the industrial park, we manage the most advanced separation processes.
Sustainability & Pharmaceutical Self-Sufficiency Indicators
Achieving one hundred percent sustainability in the domestic supply chain of plasma-derived products is the core of our operations. nojine directly fulfills the country's patients' need for life-saving drugs:
ALBUJINE® 20%
Albumin is the most abundant plasma protein, responsible for maintaining 70% to 80% of the intravascular colloid osmotic pressure.
Corporate Governance & Scientific Structure of nojine
The combination of governance background in the healthcare industry and specialized pharmaceutical knowledge is the strategic driving force of nojin Biopharma's board of directors.